期刊文献+

Halcyon 3.0双等中心调强放射治疗计划在左侧乳腺癌根治术后放射治疗中的可行性评估

Feasibility assessment of Halcyon 3.0 dual-isocenter IMRT plan in postoperative radiotherapy of radical mastectomy for left side of breast cancer
下载PDF
导出
摘要 目的:评估基于Halcyon 3.0直线加速器设计的双等中心调强放射治疗(IMRT)计划在左侧乳腺癌根治术后放射治疗中的可行性。方法:选取2022年12月至2023年6月上海中医药大学附属曙光医院收治的左侧乳腺癌根治术后放射治疗患者16例,分别基于Halcyon 3.0直线加速器设计双等中心计划和Truebeam加速器设计常规单等中心计划,统计两种计划的靶区适形度(CI)、均匀性(HI)和危及器官受照剂量等剂量学参数,对比分析Halcyon 3.0双等中心计划的剂量学表现。使用ArcCHECK和Portal Dosimetry两种剂量验证工具评估Halcyon 3.0双等中心计划射束输送的精准性。结果:Halcyon双等中心计划和Truebeam单等中心计划具有相似的计划质量。靶区的CI、HI、2%靶区体积的受照剂量(D_(2%))及98%靶区体积的受照剂量(D_(98%))等剂量学参数差异均无统计学意义(P>0.05)。Halcyon 3.0双等中心计划的机器跳数相比于Truebeam单等中心计划平均机器跳数增加366 MU,但差异无统计学意义(P>0.05)。Halcyon 3.0双等中心计划对于危及器官的保护全面优于Truebeam单等中心计划,其中Halcyon 3.0双等中心计划和Truebeam单等中心计划的20 Gy剂量覆盖的左侧肺体积(V_(20))分别为(20.41±1.56)%和(24.88±2.95)%,差异具有统计学意义(t=6.413,P<0.05),其他危及器官剂量学参数差异无统计学意义(P>0.05)。剂量容差(DT)/距离一致性(DTA)设置为2%/2 mm时,Halcyon 3.0双等中心计划在ArcCHECK和Portal Dosimetry平台的验证γ通过率分别为97.6%~98.9%和98.1%~100%;DT/DTA设置为3%/3 mm时,Halcyon 3.0双等中心计划在ArcCHECK和Portal Dosimetry平台的验证γ通过率分别为99.1%~100%和99.7%~100%,Halcyon 3.0双等中心计划射束输送精度符合临床治疗验证标准。结论:Halcyon 3.0双等中心IMRT计划在左侧乳腺癌根治术后的放射治疗中具有较高的可行性。计划剂量输送精准性高,靶区剂量充分、均匀、适形度良好,同时能够较好地限制危及器官的受照剂量。 Objective:To assess the feasibility of the designed dual-isocenter IMRT plans based on Halcyon 3.0 linear accelerator in postoperative radiotherapy of radical mastectomy for left side of breast cancer.Methods:A total of sixteen patients received the postoperative radiotherapy of radical mastectomy for left side of breast cancer at Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from December 2022 to June 2023 were retrospectively selected.The dual-isocenter plans based respectively on Halcyon 3.0 linear accelerator and Truebeam linear accelerator were designed,and the dosimetric parameters included conformity index(CI)values of target region,homogeneity index(HI)values and doses to organs at risk(OAR)of the two plans were calculated as statistic method.And then,the dosimetric performance of Halcyon 3.0 dual-isocenter plan was compared and analyzed.Utilizing two dose verification tools,ArcCHECK and Portal Dosimetry,to assess the precision of beam delivery of Halcyon 3.0 dual-isocenter plan.Results:The Halcyon dual-isocenter plan and the Truebeam single-isocenter plan had similar plan quality.There were not statistically significant differences(P>0.05)in dosimetric parameters such as CI,HI,exposure dose to 2%of the target volume(D_(2%))and exposure dose to 98%of the target volume(D_(98%)).Compared to the average monitor unit(MU)of Truebeam single-isocenter plan,the MU values of Halcyon 3.0 dual-isocenter plan increased by 366 MU,while the difference was not statistically significant(P>0.05).The Halcyon 3.0 dual-isocenter plan provided comprehensive protection for OAR,which was better than that of the Truebeam single-isocenter plan.The values of the left side of lung volume(V_(20))that were covered by 20 Gy dose of the Halcyon 3.0 dual-isocenter plan and the Truebeam single-isocenter plan were respectively 20.41%±1.56%and 24.88%±2.95%,and the difference was statistically significant(t=6.413,P<0.05).There were not significant differences in other OAR dosimetric parameters between the two kinds of plans(P>0.05).The verification pass rates of the Halcyon 3.0 dual-isocenter plans on the ArcCHECK and Portal Dosimetry platforms were respectively 97.6%-98.9%and 98.1%-100%when the ratio of dose tolerance(DT)to distance to agreement(DTA)was set at 2%/2 mm.The verification pass rates of the Halcyon 3.0 dual-isocenter plans on the ArcCHECK and Portal Dosimetry platforms were respectively 99.1%-100%and 99.7%-100%when DT/DTA was set at 3%/3 mm.The beam delivery precision of the Halcyon 3.0 dual-isocenter plan could meet verification standards of clinical treatments.Conclusion:The Halcyon 3.0 dual-isocenter IMRT plan demonstrates a higher feasibility in the postoperative radiotherapy of radical mastectomy for left side of breast cancer.The precision of dose delivery of plan is high,and the dose of target area is sufficient,uniform and favorable conformability.It can effectively limit the OAR exposure dose at the same time.
作者 曾宏伟 鄂翔宇 封悦 沈文豪 管文慧 吕民鹤 曾素 于静萍 ZENG Hong-wei;E Xiang-yu;FENG Yue(Department of Radiotherapy,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;不详)
出处 《中国医学装备》 2023年第12期20-25,共6页 China Medical Equipment
基金 上海市卫生健康委员会卫生行业临床研究专项(202340160)“PARP抑制剂在局晚期食管癌个体化放疗中的临床应用研究” 上海中医药大学科技发展项目(23KFL105)“基于Halcyon 3.0直线加速器肿瘤复杂放射治疗计划的剂量学研究” 上海中医药大学附属曙光医院中西医结合研究专项(SGZXY-202201)“调强放疗中子野优化参数对于肿瘤剂量沉积影响的研究”。
关键词 Halcyon加速器 双等中心 乳腺癌 调强放射治疗 剂量学 Halcyon accelerator Dual-isocenter Breast cancer Intensity modulated radiotherapy(IMRT) Dosimetry
  • 相关文献

参考文献3

二级参考文献26

  • 1徐晓娜,吴昊,韩树奎.左侧乳腺癌调强放疗的剂量学研究[J].中华放射肿瘤学杂志,2006,15(3):192-195. 被引量:40
  • 2Schallenkamp JM, Miller RC, Brinkmann DH, et al. Incidence of radiation pneumonitis after thoracic irradiation : dose-volume correlates. Int J Radiat Oncol Biol Phys,2007 ,67 :410-416.
  • 3Yorke ED, Jackson A. Correlation of dosimetric factors and radiation pneumonitis for non-small cell lung cancer patients in a recently completed dose escalation study. J Radiat Oncol Biol Phys, 2005,63:672-682.
  • 4Gopal R, Tucker SL, Komaki R, et al. The relationship between local dose and loss of function for irradiated lung. J Radiat Oncol Biol Phys ,2003,56 : 106-113.
  • 5Wang S, Liao Z, Wei X, et al. Analysis of clinical an dosimetric factors associated with treatment-relatedpneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3DCRT). Int J Radiat Oncol Biol Phys,2006,66:1399-1407.
  • 6Sibley GS, Mundt A J, Shapiro C, et al. The treatment of stage Ⅲ non-small cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys,1995,33:1001-1007.
  • 7Xia TY, Li HQ, Sun Qx, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage Ⅰ/Ⅱ non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2006,66 : 117-125.
  • 8Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Grosstumor volume,critical prognosic factor in patients treated with three-dimensional conformal radiation therapy for non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys,2002,52:49-57.
  • 9Bradley J, Graham MV, Winter K, et al. Toxicity and outcome resuits of RTOG 9311 : a phase Ⅰ- Ⅱ dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys, 2005,61:318-328.
  • 10Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volum e histogram parameters for predicting radiation pneumonitis after concurrent ehemoradiation for lung cancer. Int J Radiat Oncol Biol Phys ,2003,55:110-115.

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部